MAPT and Alzheimer disease: In this study, we have shown that plasma/serum BD-tau is an AD-associated marker which levels are elevated in the presence of Aβ pathology, predicts cognitive decline and associate with AD-type meta-ROI MRI signatures in the AD continuum.